Edition:
India

DBV Technologies SA (DBVT.OQ)

DBVT.OQ on NASDAQ Stock Exchange Global Select Market

21.93USD
15 Dec 2017
Change (% chg)

$0.23 (+1.06%)
Prev Close
$21.70
Open
$21.47
Day's High
$21.97
Day's Low
$21.31
Volume
79,852
Avg. Vol
131,678
52-wk High
$50.40
52-wk Low
$20.59

Chart for

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-DBV Technologies ‍announces positive data from Phase IIb trial and long-term study of Viaskin Peanut​

* ‍ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE IIB TRIAL AND LONG-TERM STUDY OF VIASKIN PEANUT​

14 Nov 2017

BRIEF-DBV Technologies reports at Sept. 30 cash position of 170.5 million euros

* CASH POSITION AT SEPT. 30, 2017 EUR 170.5 MILLION VERSUS EUR 256.5 MILLION AT DEC. 31, 2016 ‍​ Source text: http://bit.ly/2htbI61 Further company coverage: (Gdynia Newsroom)

31 Oct 2017

BRIEF-DBV Technologies ‍cash position of 170.5 million euros as of September 30​

* ‍CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2017, WERE EUR 170.5 MILLION, COMPARED TO EUR 256.5 MILLION AS OF DECEMBER 31, 2016 ​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

31 Oct 2017

BRIEF-DBV Technologies peanut allergy treatment fails to meet main goal in late-stage study

* DBV Technologies announces topline results of phase III clinical trial in peanut-allergic patients four to 11 years of age‍​

21 Oct 2017

DBV Technologies peanut allergy drug fails key study

DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down.

21 Oct 2017

DBV Technologies peanut allergy drug fails key study

Oct 20 Drug developer DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study.

21 Oct 2017

BRIEF-DBV Technologies completes blinded period in REALISE study of Viaskin Peanut

* REG-DBV TECHNOLOGIES ANNOUNCES COMPLETION OF BLINDED PERIOD IN REALISE STUDY OF VIASKIN PEANUT

12 Oct 2017

BRIEF-DBV Technologies completes enrollment in Phase III extension study of Viaskin Peanut

* REG-DBV TECHNOLOGIES ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE III EXTENSION STUDY OF VIASKIN PEANUT

29 Aug 2017

BRIEF-DBV Technologies initiates phase III study of Viaskin peanut

* REG-DBV TECHNOLOGIES INITIATES PHASE III STUDY OF VIASKIN PEANUT IN PEANUT-ALLERGIC PATIENTS ONE TO THREE YEARS OF AGE Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

02 Aug 2017

BRIEF-DBV Technologies H1 net loss widens to EUR 72.5 million

* CASH POSITION: CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2017, WERE €198.7 MILLION‍​

28 Jul 2017

Earnings vs. Estimates